Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511622
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-10
Brief Title:
Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a retrospective observational study over the period 12019 - 022024 with the aim of identifying patients with a predisposition to secondary infections
Detailed Description:
As a reference center Charité Universitaetsmedizin Berlin has been treating patients with the most severe form of acute respiratory failure known as acute respiratory distress syndrome ARDS for more than 30 years Despite lung-protective forms of ventilation and the use of extracorporeal procedures for oxygenation and decarboxylation ECMO mortality is around forty percent In addition to the primary cause of ARDS further infectious complications often develop during the course of the disease which delay recovery
The aim of this study is to investigate infectious complications ventilator-associated pneumonia reactivation of Herpes viridae pathogen resistance despite formally correct therapy fungal infections depending on the immune status
The aim of this study is to investigate infectious complications ventilator-associated pneumonia reactivation of Herpes viridae pathogen resistance despite formally correct therapy fungal infections depending on the immune status
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None